Progresses in polymeric nanoparticles for delivery of tyrosine kinase inhibitors

被引:48
作者
Foroughi-Nia, Behrouz [1 ,2 ]
Barar, Jaleh [2 ,3 ]
Memar, Mohammad Yousef [4 ]
Aghanejad, Ayuob [2 ]
Davaran, Soudabeh [1 ,2 ]
机构
[1] Tabriz Univ Med Sci, Fac Pharm, Dept Med Chem, Tabriz, Iran
[2] Tabriz Univ Med Sci, Res Ctr Pharmaceut Nanotechnol, Biomed Inst, Tabriz, Iran
[3] Tabriz Univ Med Sci, Fac Pharm, Dept Pharmaceut, Tabriz, Iran
[4] Tabriz Univ Med Sci, Infect & Trop Dis Res Ctr, Tabriz, Iran
基金
美国国家科学基金会;
关键词
Tyrosine kinase inhibitor; Theranostic agent; Cancer therapy; Nanotechnology; TARGETED DELIVERY; SYNERGISTIC THERAPY; DRUG-DELIVERY; CO-DELIVERY; ERLOTINIB; SORAFENIB; DOXORUBICIN; CARCINOMA; GEFITINIB; PACLITAXEL;
D O I
10.1016/j.lfs.2021.119642
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Tyrosine kinase inhibitors (TKIs), as an important class of chemotherapeutic drugs, induce apoptosis by altering the path of the cellular signal, resulting in cell death. However, some chemotherapeutic drugs have a limited therapeutic index and are usually destructive as well as unpredictable. In addition, the limitation of early diagnosis and inefficiency of some of the drugs in ordinary treatments lead to disease progression and decreases in the survival of cancer patients. For this purpose, various methods have been proposed, among them, nanomedicine has transpired as a modern approach for the treatment of multiple cancers. Over the last two decades, targeted therapy has been developed for cancer-specific cells/tissues and has rather restricted nonselective toxicities. In vivo and in vitro studies demonstrated nanoparticles (NPs), nano-scale drugs, and nano-carriers alone or in combination with other therapeutic, imaging, and theranostic agents would be applied as an effective approach targeting a diversity of malignant tissue. Therefore, using the latest advances in materials science and biomaterials, biology, it has happened that general diagnosis and treatment can be performed. In this review, we indicated the applications of theranostic nano-polymer and nano-liposome to TKIs delivery.
引用
收藏
页数:11
相关论文
共 50 条
[31]   Polymeric nanoparticles for drug delivery in glioblastoma: State of the art and future perspectives [J].
Madani, Fatemeh ;
Esnaashari, Seyedeh Sara ;
Webster, Thomas J. ;
Khosravani, Masood ;
Adabi, Mahdi .
JOURNAL OF CONTROLLED RELEASE, 2022, 349 :649-661
[32]   Progress in Research on Protein Tyrosine Kinase Inhibitors Progress in Research on Protein Tyrosine Kinase Inhibitors [J].
Chen, Yu .
INTERNATIONAL CONFERENCE ON FRONTIERS OF BIOLOGICAL SCIENCES AND ENGINEERING (FBSE 2018), 2019, 2058
[33]   Preparation and evaluation of PCL-PEG-PCL polymeric nanoparticles for doxorubicin delivery against breast cancer [J].
Zhang, Linhua ;
Chen, Zhuo ;
Wang, Hai ;
Wu, Shengjie ;
Zhao, Kongyin ;
Sun, Hongfan ;
Kong, Deling ;
Wang, Chun ;
Leng, Xigang ;
Zhu, Dunwan .
RSC ADVANCES, 2016, 6 (60) :54727-54737
[34]   Ovarian carcinoma biological nanotherapy: Comparison of the advantages and drawbacks of lipid, polymeric, and hybrid nanoparticles for cisplatin delivery [J].
Zhang, Yingli ;
Zhang, Ping ;
Zhu, Tao .
BIOMEDICINE & PHARMACOTHERAPY, 2019, 109 :475-483
[35]   Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors [J].
Kalra, Neetu ;
Ashai, Ali ;
Xi, Liqiang ;
Zhang, Jingli ;
Avital, Itzhak ;
Raffeld, Mark ;
Hassan, Raffit .
ONCOLOGY REPORTS, 2012, 27 (06) :1794-1800
[36]   EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future [J].
Yang, Chih-Hsin .
LUNG CANCER, 2008, 60 :S23-S30
[37]   Polymorphisms to Predict Outcome to the Tyrosine Kinase Inhibitors Gefitinib, Erlotinib, Sorafenib and Sunitinib [J].
Erdem, Lale ;
Giovannetti, Elisa ;
Leon, Leticia G. ;
Honeywell, Richard ;
Peters, Godefridus J. .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2012, 12 (15) :1649-1659
[38]   Tyrosine kinase inhibitors interstitial pneumonitis: diagnosis and management [J].
He, Yayi ;
Zhou, Caicun .
TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 :S318-S320
[39]   Have adjuvant tyrosine kinase inhibitors lost their shine? [J].
Sabari, Joshua K. ;
Chaft, Jamie E. .
ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (15)
[40]   Transport of six tyrosine kinase inhibitors: active or passive? [J].
Honeywell, Richard J. ;
Hitzerd, Sarina ;
Kathmann, Letje ;
Peters, Godefridus J. .
ADMET AND DMPK, 2016, 4 (01) :23-34